| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Walter Reed Army Medical Center, Washington, DC 20307 [S. M. B.], and The Pediatric Branch, National Cancer Institute, Bethesda, Maryland 20892 [D. E. C., F. M. B., K. G., D. G. P.]
Topotecan, a water soluble semisynthetic analogue of camptothecin, is a topoisomerase I inhibitor that has recently entered phase II clinical trials. Topotecan has shown significant preclinical activity in refractory murine tumors and in human tumor xenograft models. In addition, objective antineoplastic activity has been observed in recent adult phase I clinical trials. Topotecan is unstable in solution and is rapidly and spontaneously converted to a less active open ring form which predominates at physiological pH. This study was undertaken to better define the pharmacokinetic behavior of this highly unstable compound in both plasma and cerebrospinal fluid (CSF) and to measure the degree of CSF penetration of this novel antineoplastic agent.
Three nonhuman primates with indwelling Ommaya reservoirs received 10 mg/m2 i.v. topotecan administered as a 10-min infusion. Frequent plasma and CSF samples were obtained and immediately extracted and assayed with a reverse phase high performance liquid chromatography assay to quantitate the concentration of topotecan (lactone). Samples were then acidified and reinjected to quantitate total drug (lactone ring plus open ring).
Peak plasma concentrations of topotecan ranged from 0.27 to 0.45 µM. Plasma disappearance of the lactone ring was biexponential with a distribution half-life (t1/2
) of 22 ± 5 min and an elimination half-life (t1/2ß) of 1.3 ± 0.1 h. Total body clearance of topotecan was 72.1 ± 15.8 liters/h/m2. The volume of distribution at steady state was 88.6 ± 33.2 liters/m2. Peak CSF concentrations of topotecan occurred at 30 min following drug administration and ranged from 0.044 to 0.074 µM. CSF disappearance paralleled that in plasma. The mean ratio of the area under the CSF concentration-time curve to that in plasma was 0.32 (range, 0.29 to 0.37).
The mean CSF penetration of topotecan exceeds 30%, which is significantly greater than the penetration of most structurally similar chemotherapeutic agents. The impact of chemotherapy on the survival of patients with primary or metastatic central nervous system malignancies is very limited. Therefore, this novel antineoplastic agent is an excellent candidate for further study in patients with high risk or refractory central nervous system tumors.
1 To whom requests for reprints should be addressed, at Pediatric Branch, National Cancer Institute, Building 10, Room 13N240, 9000 Rockville Pike, Bethesda, MD 20892.
Received 11/25/92. Accepted 12/31/92.
This article has been cited by other articles:
|
|
 |
|
  B. B. Freeman III, L. C. Iacono, J. C. Panetta, A. Gajjar, and C. F. Stewart Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma Neuro-oncol, April 1, 2006; 8(2): 89 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mialon, M. Sankinen, H. Soderstrom, T. T. Junttila, T. Holmstrom, R. Koivusalo, A. C. Papageorgiou, R. S. Johnson, S. Hietanen, K. Elenius, et al. DNA Topoisomerase I Is a Cofactor for c-Jun in the Regulation of Epidermal Growth Factor Receptor Expression and Cancer Cell Proliferation Mol. Cell. Biol., June 15, 2005; 25(12): 5040 - 5051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Stewart, L. C. Iacono, M. Chintagumpala, S. J. Kellie, D. Ashley, W.C. Zamboni, M.N. Kirstein, M. Fouladi, L. G. Seele, D. Wallace, et al. Results of a Phase II Upfront Window of Pharmacokinetically Guided Topotecan in High-Risk Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor J. Clin. Oncol., August 15, 2004; 22(16): 3357 - 3365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ostermann, C. Csajka, T. Buclin, S. Leyvraz, F. Lejeune, L. A. Decosterd, and R. Stupp Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients Clin. Cancer Res., June 1, 2004; 10(11): 3728 - 3736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Neville, R. A. Parise, P. Thompson, A. Aleksic, M. J. Egorin, F. M. Balis, L. McGuffey, C. McCully, S. L. Berg, and S. M. Blaney Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates Clin. Cancer Res., April 1, 2004; 10(7): 2525 - 2529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Wong and A. Berkenblit The Role of Topotecan in the Treatment of Brain Metastases Oncologist, February 1, 2004; 9(1): 68 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Blaney, R. Heideman, S. Berg, P. Adamson, A. Gillespie, J. R. Geyer, R. Packer, K. Matthay, K. Jaeckle, D. Cole, et al. Phase I Clinical Trial of Intrathecal Topotecan in Patients With Neoplastic Meningitis J. Clin. Oncol., January 1, 2003; 21(1): 143 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bomgaars, S. L. Berg, and S. M. Blaney The Development of Camptothecin Analogs in Childhood Cancers Oncologist, December 1, 2001; 6(6): 506 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Fisher, C. Scott, D. R. Macdonald, C. Coughlin, and W. J. Curran Phase I Study of Topotecan Plus Cranial Radiation for Glioblastoma Multiforme: Results of Radiation Therapy Oncology Group Trial 9507 J. Clin. Oncol., February 15, 2001; 19(4): 1111 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Uhm, N. P. Dooley, A. P. Kyritsis, J. S. Rao, and C. L. Gladson Vitronectin, a Glioma-derived Extracellular Matrix Protein, Protects Tumor Cells from Apoptotic Death Clin. Cancer Res., June 1, 1999; 5(6): 1587 - 1594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Winter and M. Weller Potentiation of CD95L-Induced Apoptosis of Human Malignant Glioma Cells by Topotecan Involves Inhibition of RNA Synthesis but Not Changes in CD95 or CD95L Protein Expression J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1374 - 1382. [Abstract] [Full Text]
|
|
|
|
|
|
P. C. Adamson All-Trans-Retinoic Acid Pharmacology and Its Impact on the Treatment of Acute Promyelocytic Leukemia Oncologist, October 1, 1996; 1(5): 305 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Berg and D. G. Poplack Treatment of Meningeal Malignancy Oncologist, February 1, 1996; 1(1): 56 - 61. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
